Factors Associated With Age Disparities Among Cancer Clinical Trial Participants
Ethan B. Ludmir(The University of Texas MD Anderson Cancer Center), Clifton D. Fuller(The University of Texas MD Anderson Cancer Center), Benjamin D. Smith(The University of Texas MD Anderson Cancer Center), Noam A. VanderWalde(University of Tennessee Health Science Center), Amit Jethanandani(University of Tennessee Health Science Center), Daniel R. Gomez(The University of Texas MD Anderson Cancer Center), Andres F. Espinoza(Baylor College of Medicine), Grace L. Smith(The University of Texas MD Anderson Cancer Center), Austin B. Miller(The University of Texas Health Science Center at Houston), Albert C. Koong(Stanford University), Reshma Jagsi(University of Michigan–Ann Arbor), Steven H. Lin(The University of Texas MD Anderson Cancer Center), Bruce D. Minsky(Harvard University), Jacob Mandel(Baylor College of Medicine), Charles R. Thomas(Oregon Health & Science University), Timothy A. Lin(The University of Texas MD Anderson Cancer Center), W. Ian P. Mainwaring(Baylor College of Medicine), Thomas E. Stinchcombe(Duke Medical Center)
Cited by 229
Related Papers
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
|Cancer Research|2014|7.2k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
|The Lancet Oncology|2016|1.1k
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646